L.E.K.'s latest Executive Insight with Pierre Jacquet, M.D., Ph.D. Ricardo Brau Anne Dhulesia details a comprehensive analysis of Biopharma M&A trends and implications for Pharma executives and Boards. With over a decade of experience advising clients on Biopharma M&A, our analyses uncovered key trends in the market that may continue to influence deal-making in 2024 and beyond. Importantly, our work closely examined clinical outcomes and commercial performance of historical M&A deals, highlighting key insights for industry decision-makers to consider for transacting deals in today's environment. Given these learnings, we highlight 5 key strategic priorities to successfully navigate the current M&A environment. Link:
Bradley F. Hagan’s Post
More Relevant Posts
-
By analyzing the financials of dozens of #BigPharma firms, we can pinpoint the global hubs that drive much of the industry’s innovation. See the map below for an overview of where the world’s 50 top #pharmaceutical companies & corresponding #pharma hubs are headquartered: https://lnkd.in/gNbkMHVB #RandD #PharmaceuticalIndustry
Top 10 global Big Pharma hubs in 2023 | Drug Discovery & Development
https://www.drugdiscoverytrends.com
-
International Director at SwedenBIO - creating strategic partnerships within life science
Have you done your homework on market analysis of your product? Come and learn how Citeline can help you.
🔍📈 Data Driven Business Growth Seminar We're excited to announce an exclusive seminar hosted by Citeline in collaboration with #SwedenBIO, exploring the pivotal role of data in driving business growth within the pharmaceutical landscape. 📅 May 15, 2024 🕐 Time: 11:00 AM - 12:00 PM 📍SwedenBIO, Wallingatan 24, Stockholm In today's rapidly evolving pharmaceutical industry, leveraging data, expertise, and insights is paramount for sustainable growth. From clinical strategies to commercialization endeavors, data-driven decisions shape the trajectory of success for pharma and biotech companies. This seminar will focus on how #Citeline can help pharma/biotech companies with what comes next, including how to capitalize on opportunities, mitigate risks and drive growth. More info and registration: https://lnkd.in/dwEAFxpN Duncan E. Jean-Marc Mezin Mina Hanna #DataDrivenGrowth #PharmaIndustry #BusinessInsights
-
-
Five leaders from Acadia Pharmaceuticals Inc., Ardelyx, Inc., Ascendis Pharma, Bristol Myers Squibb and Lundbeck share their approaches to redefining biopharma Market Access💡https://bit.ly/3N6SpOF Learn how to empower your organization with the right strategy, innovative mindset, and tools to improve the #patientexperience. #biopharma #marketaccess #patientaccess #expertinsights #patientexperienceinnovators
-
-
Learn how to empower your organization with the right strategy, innovative mindset, and tools to improve the #patientexperience. #biopharma #marketaccess #patientaccess #expertinsights #patientexperienceinnovators
Five leaders from Acadia Pharmaceuticals Inc., Ardelyx, Inc., Ascendis Pharma, Bristol Myers Squibb and Lundbeck share their approaches to redefining biopharma Market Access💡https://bit.ly/3N6SpOF Learn how to empower your organization with the right strategy, innovative mindset, and tools to improve the #patientexperience. #biopharma #marketaccess #patientaccess #expertinsights #patientexperienceinnovators
-
-
On both sides of the Atlantic pharma companies are presenting cases to the courts and to national regulators that the innovation cash pipelines will be disrupted, forcing them to either cut back and delay launches or move operations to Asia Pacific or Latin America. Find out more in our newly published whitepaper featuring industry experts: · Christoph Glaetzer, Dipl.Kfm., Chief Global Value and Access at Johnson & Johnson Innovative Medicine · Ricardo Werner Marek, President Europe & Canada at Takeda · Andy Powrie-Smith, Executive Director, Communications & Partnerships at EFPIA - European Federation of Pharmaceutical Industries and Associations Access the full whitepaper here: https://bit.ly/3Vh46Y2
-
-
In this edition of Founders’ Q2 2024 Pharma Services M&A and Valuations Newsletter, our team shares valuable insights from the industry. The newsletter includes data points highlighting: • Market trends and insights • Market & buyer landscape map • M&A deal volume • Notable recent transactions If you or someone you know has questions about the market around the pharmaceutical services industry, please feel free to reach out to Michael White, Managing Director of Founders’ Healthcare Team & Pharma Services Sector Coverage Leader, for more information.
Pharma Services M&A and Valuations | Q2 2024
https://foundersib.com
-
🔍 Unveiling the PBM Puzzle: Navigating Pharma Costs with CSuitePharma 🌐💊 In the ever-evolving world of pharmaceuticals, Pharmacy Benefit Managers (PBMs) take center stage in the debate on rising drug prices. 💰 Our latest article breaks down the PBM role, exploring both sides of the reform argument with insightful stats. 📊 Swipe left to unravel the complexities of drug costs and discover the nuances surrounding PBM transparency, market dominance, and the quest for a balanced solution. 🤝💡 Dive into the conversation on healthcare reform with CSuitePharma Insights. 🚀 #PBMReform #PharmaEconomics #CSuitePharma #HealthcareInsights #DrugCosts #HealthcareReform #TransparencyMatters 💊🔗 https://lnkd.in/gdQ-XFSb
Unlocking the PBM Dilemma: Navigating Drug Costs in Pharma
csuitepharma.com
-
An interesting look at the variability of launch performance even among the largest and most experienced pharma players. As with our analysis of biopharma M&A, this analysis highlights how critical it is to proactively invest in lifecycle planning and carefully evaluate efforts to diversify beyond core areas https://lnkd.in/gzcE2p6K
Variability in Large Pharma Launch Performance | L.E.K. Consulting
lek.com
-
This McKinsey article underscores a pivotal shift: small biopharma companies increasingly launch their own drugs. This trend, driven by favorable business cycles, talent availability, and vendor support, allows these companies to navigate commercialization independently. At Luminyst, these insights resonate with us. Our focus on deep operational understanding, early commercial planning, and agile project tracking aligns with McKinsey’s success factors for first-time launchers. We're committed to empowering innovative solutions in the biopharma landscape. Read more: https://lnkd.in/ehNnT3EZ #pharma #biopharma #commercialreadiness #productdevelopment #healthcare #poductlaunch
First-time launchers in the pharmaceutical industry
mckinsey.com
-
Field Force Effectiveness | Business Intelligence | Learning and Development | Coaching | Market Research | Sales | Customer Relation Management
It may be a coincidence (or not) but the companies with the greatest investment in R&D are also the ones that have had the greatest growth in recent years.
📊 Top Large Pharmas by R&D investment 👇 What is the most efficient way to spend cash for large pharmaceutical companies? Generating returns is vital for funding innovations that will ultimately benefit patients. 🔎 I made this graph from an analysis by Evaluate Pharma looking at the large pharma spending behavior over the last 10 years. The graph is focused on how much internal R&D spending is prioritized over M&As and licensing deals. It shows the percentage of R&D spending out of the combined expenditure on M&As, licensing, and R&D over the last 10 years. Highlighting very different strategies for future growth. 🔬 Novo Nordisk and Roche are top R&D spenders, dedicating over 70% of their total expenditure to in-house drug development. 🤝 Takeda and AbbVie focused heavily on mergers with AbbVie’s notable acquisition of Allergan in 2020 being a significant deal. 💊 Amgen was the only company to spend more than 10% on product-level deals, primarily due to its $13.4 billion acquisition of worldwide rights to Celgene’s psoriasis drug Otezla in 2019. Source: Citeline 👏 Evaluate Pharma, BiomedTracker.
-